New Study Designed To Improve Outcomes In Women With Metastatic Breast Cancer

June 15, 1998

LEXINGTON, KY (June 15, 1998) -- Researchers at the University of Kentucky Markey Cancer Center recently announced the beginning of a novel clinical trial designed to improve the outcome of metastatic breast cancer in some women. The most frequently diagnosed non-skin cancer among women in the United States, breast cancer was expected to kill more than 40,000 women in 1997.

Decades of research with traditional anti-cancer therapies, such as conventional chemotherapy and hormone manipulation, have improved outcomes only marginally, although many women do live longer as a result.

"Women with advanced breast cancer benefit from transplants, but are rarely cured," said Kenneth Foon, M.D., chief of hematology/oncology and director of the UK Markey Cancer Center. "It is our hope that by adding a vaccine therapy to stimulate an immune response, we will destroy residual tumor cells that remained following chemotherapy."

Foon and Donna Reece, M.D., a hematologist/oncologist and director of the Blood and Marrow Transplant Outpatient Clinic, have combined two treatment methods into a single treatment program to improve survival rates.

The first requires high-dose chemotherapy to kill the cancer cells. The second involves the administration of a vaccine to enhance the body's immunity against cancer cells.

High-dose chemotherapy and autologous stem cell rescue are the first treatment steps. Autologous stem cell rescue involves the use of the patient's own blood to obtain stem cells, the precursors of all blood cells. Stem cells will regenerate bone marrow function in the patient after high-dose chemotherapy.

Because high-dose chemotherapy will destroy the patient's bone marrow, stem cells are collected after a small dose of chemotherapy and growth factors. The purified cells are frozen in liquid nitrogen for later use.

Metastatic breast cancer recurs in up to 90 percent of cases after high-dose therapy. To combat the recurrence of disease, a vaccine, called an anti-idiotypic monoclonal antibody, is administered as the second component of the new treatment. Developed by Foon and colleague Malaya Chatterjee, Ph.D., professor of internal medicine, UK College of Medicine, the vaccine mimics a protein found on tumor cell surfaces in order to stimulate an immune response in the body.

The patient's body is unable to recognize tumor cells as foreign, and therefore does not generate an immune response against the cancer. The vaccine lets the body recognize cancer cells as foreign and to mount an immune response against them. Accordingly, use of the vaccine after a transplant - when the volume of residual tumor cells is relatively low - may be the ideal situation.

However, an inevitable period of severe suppression in the patient's immune system is seen following a stem cell transplant. Until the immune system fully recovers, the vaccine likely would not stimulate the patient's re-emerging immune defense mechanisms against the cancer. In light of this fact, the patient's immune system is stimulated by the vaccine before stem cell collection. Cells that "remember" immunity are, therefore, collected with the stem cells. The patient receives these with the stem cell transplant after high-dose chemotherapy.

Supplemental vaccinations begin again about one week after the transplant and will continue once a month for up to two years.

The treatment plan:Criteria for women to participate in the study:
-end-


University of Kentucky Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.